231 related articles for article (PubMed ID: 19153152)
1. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.
Smith GS; Kramer E; Ma Y; Hermann CR; Dhawan V; Chaly T; Eidelberg D
Brain; 2009 Feb; 132(Pt 2):392-401. PubMed ID: 19153152
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease.
Klaassens BL; van Gerven JMA; Klaassen ES; van der Grond J; Rombouts SARB
Neuroimage; 2019 Oct; 199():143-152. PubMed ID: 31112788
[TBL] [Abstract][Full Text] [Related]
3. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects.
Smith GS; Ma Y; Dhawan V; Gunduz H; Carbon M; Kirshner M; Larson J; Chaly T; Belakhleff A; Kramer E; Greenwald B; Kane JM; Laghrissi-Thode F; Pollock BG; Eidelber D
Synapse; 2002 Aug; 45(2):105-12. PubMed ID: 12112403
[TBL] [Abstract][Full Text] [Related]
4. Serotonin modulation of cerebral glucose metabolism in depressed older adults.
Smith GS; Kramer E; Hermann C; Ma Y; Dhawan V; Chaly T; Eidelberg D
Biol Psychiatry; 2009 Aug; 66(3):259-66. PubMed ID: 19368900
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome.
Smith GS; Workman CI; Kramer E; Hermann CR; Ginsberg R; Ma Y; Dhawan V; Chaly T; Eidelberg D
Am J Geriatr Psychiatry; 2011 Jan; 19(1):53-63. PubMed ID: 21218565
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.
Smith GS; Kahn A; Sacher J; Rusjan P; van Eimeren T; Flint A; Wilson AA
Am J Geriatr Psychiatry; 2011 Dec; 19(12):1016-25. PubMed ID: 21841458
[TBL] [Abstract][Full Text] [Related]
7. rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Shirayama Y; Takahashi M; Oda Y; Yoshino K; Sato K; Okubo T; Iyo M
Brain Imaging Behav; 2019 Feb; 13(1):75-86. PubMed ID: 29247294
[TBL] [Abstract][Full Text] [Related]
8. Serotonin modulation of cerebral glucose metabolism in normal aging.
Goldberg S; Smith GS; Barnes A; Ma Y; Kramer E; Robeson K; Kirshner M; Pollock BG; Eidelberg D
Neurobiol Aging; 2004 Feb; 25(2):167-74. PubMed ID: 14749134
[TBL] [Abstract][Full Text] [Related]
9. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.
Matthews DC; Mao X; Dowd K; Tsakanikas D; Jiang CS; Meuser C; Andrews RD; Lukic AS; Lee J; Hampilos N; Shafiian N; Sano M; David Mozley P; Fillit H; McEwen BS; Shungu DC; Pereira AC
Brain; 2021 Dec; 144(12):3742-3755. PubMed ID: 34145880
[TBL] [Abstract][Full Text] [Related]
10. Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation.
Klaassens BL; Rombouts SA; Winkler AM; van Gorsel HC; van der Grond J; van Gerven JM
Hum Brain Mapp; 2017 Jan; 38(1):308-325. PubMed ID: 27622387
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
12. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
13. Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression.
Diaconescu AO; Kramer E; Hermann C; Ma Y; Dhawan V; Chaly T; Eidelberg D; McIntosh AR; Smith GS
Hum Brain Mapp; 2011 Oct; 32(10):1677-91. PubMed ID: 20886575
[TBL] [Abstract][Full Text] [Related]
14. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
15. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
16. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
17. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
[TBL] [Abstract][Full Text] [Related]
19. Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans.
Geday J; Hermansen F; Rosenberg R; Smith DF
Synapse; 2005 Mar; 55(4):224-9. PubMed ID: 15668991
[TBL] [Abstract][Full Text] [Related]
20. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
